LexDanaLexDanabeta
Inventor

Thierry Nivaggioli

Inventor
Atherton, CA, US

Overview

48→
Patents
2001–2021
Patent span
Human necessities
Primary field (CPC A)

Patents· 48 as inventor

Public. Assignee & technology derived from the patent record. Each patent links to its LexDana page.

A61Kprimary
A61KPreparations for medical, dental or toiletry purposes39%
A61PSpecific therapeutic activity of chemical compounds or medicinal preparations36%
A61FFilters implantable into blood vessels13%
A01CPlanting3%
Y10TTechnical subjects covered by former us classification3%
A61LMethods or apparatus for sterilising materials or objects in general2%
B01FMixing, e.g. dissolving, emulsifying or dispersing2%
C08LCompositions of macromolecular compounds1%
PatentTitleYear
10,881,608Biodegradable intravitreal tyrosine kinase implants202110,874,605Extended release biodegradable ocular implants202010,702,539Ocular implant made by a double extrusion process202010,154,960Extended release biodegradable ocular implants201810,076,492Biodegradable intravitreal tyrosine kinase implants201810,076,526Ocular implant made by a double extrusion process20189,452,156'Formulations and methods for vascular permeability-related diseases or conditions'20169,387,165'Rapamycin formulations and methods of their use'20169,381,153'Liquid formulations for treatment of diseases or conditions'20169,327,059'Steroid-containing sustained release intraocular implants and related methods'20169,233,070'Biodegradable intravitreal tyrosine kinase implants'20169,192,511'Ocular implant made by a double extrusion process'20158,974,812'Extended release biodegradable ocular implants'20158,968,766'Sustained release intraocular implants containing tyrosine kinase inhibitors and related methods'20158,962,009'Sustained release intraocular implants and related methods'20158,927,005'Liquid formulations for treatment of diseases or conditions'20158,895,049'Extended release biodegradable ocular implants'20148,778,381'Ocular implant made by a double extrusion process'20148,771,722'Methods of treating ocular disease using steroid-containing sustained release intraocular implants'20148,715,709'Sustained release intraocular implants and methods for treating ocular neuropathies'20148,685,435'Extended release biodegradable ocular implants'20148,663,639'Formulations for treating ocular diseases and conditions'20148,658,667'Stable formulations, and methods of their preparation and use'20148,637,070'Rapamycin formulations and methods of their use'20148,512,738'Biodegradable intravitreal tyrosine kinase implants'20138,506,987'Ocular implant made by a double extrusion process'20138,492,400'Stable formulations, and methods of their preparation and use'20138,486,960'Formulations and methods for vascular permeability-related diseases or conditions'20138,440,216'Sustained release intraocular implants and related methods'20138,409,607'Sustained release intraocular implants containing tyrosine kinase inhibitors and related methods'20138,404,267'Sustained release intraocular implants containing tyrosine kinase inhibitors and related methods'20138,367,097'Liquid formulations for treatment of diseases or conditions'20138,318,070'Ocular implant made by a double extrusion process'20128,298,570'Sustained release intraocular implants and related methods'20128,263,110'Sustained release intraocular implants and related methods'20128,257,730'Steroid-containing sustained release intraocular implants and related methods'20128,222,271'Formulations and methods for vascular permeability-related diseases or conditions'20128,147,865'Steroid-containing sustained release intraocular implants and related methods'20128,119,154'Sustained release intraocular implants and related methods'20128,048,445'Ocular implant made by a double extrusion process'20118,034,370'Ocular implant made by a double extrusion process'20118,034,366'Ocular implant made by a double extrusion process'20117,771,742'Sustained release intraocular implants containing tyrosine kinase inhibitors and related methods'20107,585,517'Transscleral delivery'20096,635,282'Gellan gum tablet film coating'20036,627,225'Gellan gum tablet coating'20036,395,298'Gellan gum tablet coating'20026,326,028'Alginate and gellan gum as tablet coating'2001

Career & activity timeline

Assembled from patent assignee/location history and declaration credentials.

2001–2003Based in San Francisco, CA, US· patent location history
2009–2021Based in Atherton, CA, US· patent location history
2010–2021Patents assigned to ALLERGAN INC (32)· patent assignee history
2010–2014Based in Los Altos Hills, CA, US· patent location history
2011–2014Based in Los Altos, CA, US· patent location history
2012–2015Patents assigned to NIVAGGIOLI THIERRY (21)· patent assignee history
2012–2016Patents assigned to SANTEN PHARMACEUTICAL CO LTD (11)· patent assignee history
2012–2015Patents assigned to HUANG GLENN T (9)· patent assignee history
2012–2014Patents assigned to WEBER DAVID A (7)· patent assignee history
2013Based in Irvine, CA, US· patent location history

Inventor activity

Assignee and location history derived from the patent record.

Assignees
AssigneePatentsSpan
ALLERGAN INC322010–2021
NIVAGGIOLI THIERRYself212012–2015
SANTEN PHARMACEUTICAL CO LTD112012–2016
HUANG GLENN T92012–2015
WEBER DAVID A72012–2014
Locations
LocationPatentsSpan
Atherton, California, US312009–2021
Los Altos Hills, California, US92010–2014
San Francisco, California, US42001–2003
Los Altos, California, US32011–2014
Irvine, California, US12013